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to adherence with ACE inhibitors, beta-blockers and ARBs. RESULTS: RAMQ data 
were obtained for a total of 82,018 patients with a diagnosis of CHF. Among these 
patients, 59.9% used an ACE inhibitor, 59.5% a beta-blocker, 28.4% an ARB. and 
12,344 (15.1%) had used spironolactone. Incidence of hyperkalemia (3.3% vs. 1.4%) 
and of gynecomastia (1.8% vs. 0.7%) was signiﬁcantly higher among spironolactone 
users compared to non users (p  0.001). Treatment compliance was signiﬁcantly 
lower with spironolactone compared to ACE inhibitors, beta-blockers and ARBs 
(45.6% vs. 56.1%, 59.7%, 57.0% respectively; p  0.001). Persistence to treatment 
over a one year period was also lower with spironolactone compared to ACE inhibi-
tors, beta-blockers and ARBs (50.7% vs. 64.5%, 70.4%, 66.3% respectively; 
p  0.001) CONCLUSIONS: Although the use of spironolactone may be beneﬁcial 
for patients with CHF, its usefulness is limited by the incidence of adverse events and 
its relatively poor treatment compliance.
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OBJECTIVES: To compute the frequency of the bradycardia associated with Atenolol 
Hydrochloride for possible toxic signal detection (SD) by extracting the data from the 
Canadian Adverse Drug Reaction Monitoring Program (CADRMP) ‘MedEffec’. 
METHODS: Appropriate statistical methods such as, Proportional Reporting Ratio 
(PRR); Reporting Odds Ratio (ROR); the Chi-Square (C2) statistic; Observed to 
Expected Ratio (O/E) and the Du Mouchel method were used for Adverse Drug Reac-
tion (ADR) signal detection. Signiﬁcance of C2 and other calculated statistics, e.g., PRR 
and ROR was based on a composite criterion of regulatory guidelines e.g. value q4.0 
for C2, and q3.0 for the rest to be considered as signal detection. RESULTS: The bra-
dycardia associated with Atenolol Hydrochloride was 8 (A) and bradycardia associ-
ated with all other antihypertensive medicines was 48 (C). All other adverse drug 
reactions (except bradycardia) caused by Atenolol Hydrochloride were 235 (B) and 
all other ADR (but not bradycardia) associated with all other antihypertensive medi-
cines (except Atenolol Hydrochloride) were 2593 (D). The value of PRR was 1.8134; 
Reporting Odds Ratio was 1.8390 and the C2 statistic value was 2.2915. The O/E 
ratio was 1.7047 and 1.6972 was the value of PRR calculated by the Du Mouchel 
method. CONCLUSIONS: Atenolol hydrochloride, a selective B1 receptor antagonist 
introduced in 1976 as a replacement for propranolol in the treatment of hypertension 
shows a number of serious and non-serious adverse drug reactions. Signal detection 
of bradycardia associated with Atenolol Hydrochloride was not found signiﬁcant by 
any of the statistical method. However, since the calculated statistics were consider-
able, albeit not signiﬁcant, the possibility of bradycardia-Atenolol Hydrochloride 
pairing should still be analyzed from larger databases.
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OBJECTIVES: To utilize an integrated medical-drug-dental claims database to under-
stand the relationship between periodontal disease, statin use, and cardiovascular 
disease (CAD) events. METHODS: Patients were selected from the 2005–2007 
MarketScan® Dental Database who had periodontal disease, based on diagnosis 
or dental procedure codes, and 12 months of continuous enrollment prior to the peri-
odontal disease diagnosis (index date). The Dental Database includes medical, phar-
macy, and dental records for 6.5 million patients. Patients were divided into two 
cohorts—treated and not treated with statins—and followed for 12 months for evi-
dence of CAD events. CAD patients were identiﬁed using ICD-9-CM diagnosis codes 
414.00–414.07 and 414.8–9. RESULTS: There were 157,915 patients identiﬁed having 
periodontal disease and meeting the enrollment criteria; 155,802 (98.7%) did not have 
a CAD event in the 12 months prior to the index date. Twenty-ﬁve percent (40,049) of 
patients with periodontal disease were on statins during this period. Post-periodontal 
diagnosis, the rate of CAD event was 0.42 percent (N  652) for statin-treated patients. 
The rate of CAD event post-periodontal diagnosis date was 1.16 percent (N  1808) 
for untreated patients. Controlling for differences in demographics and preexisting 
clinical conditions, patients not treated with statins prior to being diagnosed with peri-
odontal disease are 2.77 times more likely to have a CAD event in the following 12 
months than treated patients. CONCLUSIONS: Integrating dental claims with medical 
and drug claims provides an opportunity to follow a large cohort of patients and 
determine the relationships between oral and medical care and drug utilization. Statin 
treatment for an at-risk population with periodontal disease may mitigate the risk of 
a CAD event. A longer follow-up period will further elucidate this relationship.
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OBJECTIVES: Assess associations between the Deyo-Charlson comorbidity index 
(DCI) score and cardiovascular disease (CVD) event risk among primary (PR) and 
secondary risk (SR) dyslipidemia patients in a managed care setting. METHODS: A 
retrospective analysis of patients aged q18 years with laboratory results from a com-
plete ﬁrst lipid panel (index date) between January 1, 2002-February 28, 2005 was 
performed using an integrated managed care research database. Inclusion criteria were 
patients with minimum of 12 months pre- and post-index date follow-up, without 
lipid-modifying medication use at least 6 months prior to index date, and at least one 
of LDL-C, HDL-C, or TG at sub-optimal level per multiple national treatment 
guidelines. Associations between pre-index DCI score and 3-year CVD event risk was 
estimated between PR and SR patients using a multivariate logistic regression model 
after controlling for demographic and clinical variables. RESULTS: A total of 45,716 
patients were identiﬁed, 57.8% (n  26,407) were PR. Statistical signiﬁcance was 
observed between the 2 groups at baseline in terms of percent males (SR: 56.7% vs. 
48.3%: PR; p  0.0001), DCI score (SR: 0.16 o 0.43 vs. PR: 0.64 o 0.72; p  0.0001), 
LDL-C (SR: 129.4 o 35.1 vs. PR: 126.7 o 34.8 mg/dL; p  0.0001), HDL-C 
(SR: 42.0 o 11.2 vs. PR: 48.4 o 14.0 mg/dL; p  0.0001), and TG (SR: 179.1 o 79.3 
vs. PR: 161.1 o 79.1 mg/dL; p  0.0001). Regression analysis showed that every one 
unit increase in pre-index DCI score was associated with a 34% [Odds Ratio 
(OR): 1.34 (1.27–1.41); p  0.05] higher likelihood to experience a CVD event 
at 3 years among SR patients versus 32% [OR: 1.32 (1.20–1.46); p  0.05] for PR 
patients. CONCLUSIONS: SR dyslipidemia patients with a higher DCI score were 
associated with a higher CVD event risk versus PR patients. Further research on this 
association and subsequent impact on long-term clinical and economic outcomes is 
needed.
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OBJECTIVES: Assess associations between the Deyo-Charlson index (DCI) score and 
annual cardiovascular disease (CVD) event risk and attributable total health care costs 
(THC) between patients initiating niacin extended-release (NER) plus simvastatin 
(NER/S) and simvastatin plus ezetimibe (S/E) ﬁxed-dose therapy among patients with 
prior CVD. METHODS: A retrospective analysis of patients aged q18 years newly 
initiating S/E or NER/S therapy (initial therapy of NER added to existing simvastatin 
therapy) between January 1, 2001-June 30, 2006 (index date) was performed using a 
large integrated managed care research database. Patients with a minimum of 12 
months pre- and post-index date follow-up and a diagnosis of CVD at some time 
during 12 months prior to index date were included. Associations between pre-index 
date DCI score, CVD event risk, and THC [sum of inpatient, emergency room, and 
outpatient visit costs] were estimated using Cox proportional hazards regression 
model and multivariate generalized linear model, respectively. RESULTS: A total of 
7065 study patients were identiﬁed initiating S/E (n  6513) or NER/S (n  552). 
NER/S patients were signiﬁcantly younger (58.5 o 9.2 years vs. 61.3 o 10.2 years; p 
 0.0001) and more likely to be male (85.1% vs. 67.9%; p  0.0001). Pre-index date 
DCI score (1.3 o 1.3 vs. 1.4 o 1.6; p  0.1018) was comparable between the two 
groups. Cox regression showed that every one unit increase in pre-index date DCI 
score was associated with a 27% [Hazard Ratio (HR): 1.27 (1.22–1.32); p  0.05] 
higher likelihood to experience a post-index CVD event. Multivariate regression 
showed that every one unit increase in pre-index date DCI score was associated with 
a 38% (Coefﬁcient: 1.38, 95% CI: 1.30–1.47; p  0.0001) increase in mean annual 
CVD THC. CONCLUSIONS: High-risk patients with prior CVD and with an increas-
ing DCI score were associated with a higher CVD event risk and total annual CVD-
attributable THC. Further studies on dyslipidemia treatment strategies on higher risk 
patients are warranted.
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Despite substantial research showing that peripheral arterial disease (PAD) increases 
the risk for heart attack, stroke, amputation and other vascular-related conditions, 
PAD is potentially under-diagnosed and under-treated. Once diagnosed, research 
indicates that PAD merits aggressive management of all cardiovascular disease (CVD) 
risk factors. OBJECTIVES: The primary objective was to assess the prevalence of 
lower extremity PAD through Ankle-Brachial Index (ABI) measurement in patients at 
moderate CVD risk, with no overt vascular diseases nor diabetes mellitus. Secondary 
objectives included the prevalence and treatment of CVD risk factors and patient/phy-
sicians’ determinants for PAD under-diagnosis. METHODS: PANDORA Belgium was 
part of a non-interventional, cross-sectional, multi-centre study conducted in six 
European countries. Selection of general practitioners (GPs) was based on ABI mea-
surement training according ACC/AHA guidelines. RESULTS: A total of 119 GPs in 
Belgium recruited 1510 evaluable patients. The mean prevalence of asymptomatic 
PAD, deﬁned as ABI  0.90, was 7%, the lowest prevalence in the 6 countries (mean 
18%). Mean LDL-C for asymptomatic PAD patients was 125 mg/dl. Sixty-seven 
percent of untreated dyslipidemic subjects, diagnosed with asymptomatic PAD, had 
LDL-C  130 mg/dl. 32% of the Belgian patients were treated with statins. Patients 
